Trial · NCT04167813
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hallucinations | 12 weeks | Scale for Assessment of Positive Symptoms-Hallucinations (0-35 points, higher scores indicate greater severity of hallucinations |
| Secondary | Delusions | 2, 4, 6, 12, 18, 24 weeks | Scale for Assessment of Positive Symptoms-Delusions (0-65 points, higher scores indicate greater symptom severity |
| Secondary | Safety and tolerability | 2, 4, 6, 12, 18, 24 weeks | Number of Participants With Treatment-Related Adverse Events |
| Secondary | Health related quality of life | 6, 12, 18, 24 weeks | EQ-5D-5L |
| Secondary | Cost effectiveness | 2, 4, 6, 12, 18, 24 weeks | Health and social service utilisation |
| Secondary | Pharmacokinetics, plasma concentrations of the study drug | 6, 12 weeks | Measured using a validated HPLC/MS assay |
| Secondary | Hallucinations | 2, 4, 6, 18, 24 weeks | Scale for Assessment of Positive Symptoms-Hallucinations (0-35 points, higher scores indicate greater severity of hallucinations |
| Secondary | Global illness severity | 2, 4, 6, 12, 18, 24 weeks | Clinical Global Impression of Severity Scale (1-7, higher scores indicate greater severity) |
| Secondary | Non-motor symptoms | 2,4,6,12,18,24 weeks | Non-motor symptoms scale (0-120, higher scores indicate greater severity |
| Secondary | Cognition | 12 weeks | Standardised Mini-Mental State Examination (0-30, higher scores indicate better performance) |
| Secondary | Hallucinations | 6, 12 weeks | University of Miami Parkinson's disease Hallucinations Questionnaire (0-15, where higher scores indicate greater symptom severity) |
| Secondary | Feasibility and Acceptability of Video Consultation | baseline, 6 and 12 weeks | The feasibility of video consultation will be measured at baseline, 6 and 12 weeks by the proportion of participants who were able to successfully attend on at least one occasion, the proportion who successfully attended all three assessments, and a Satisfaction questionnaire that allows both quantitative and qualitative information to be collected. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04167813/registered